High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells

Cancer Letters

Volumn 310, Issue 2, 2011, Pages 140-147

  Yokomizo, Chihiro ^a   Yamaguchi, Kanji ^a   Itoh, Yoshito ^a   Nishimura, Takeshi ^a   Umemura, Atsushi ^a   Minami, Masahito ^a   Yasui, Kohichiroh ^a   Mitsuyoshi, Hironori ^a   Fujii, Hideki ^a   Tochiki, Nozomi ^a   Nakajima, Tomoki ^b   Okanoue, Takeshi ^c   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Saiseikai Kyoto Hospital   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

E cadherin; HCC; Overall survival; P300; Tumor invasion

Indexed keywords

BETA CATENIN; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P300; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION;

AGED; APOPTOSIS; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL DEDIFFERENTIATION; CELL LINE, TUMOR; CYCLIN D1; DOWN-REGULATION; E1A-ASSOCIATED P300 PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

GASTROPODA;

EID: 80051687089     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.030     Document Type: Article

References (43)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010.
2. Treiber G., Wex T., Rocken C., Fostitsch P., Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2006, 132:699-708.
3. Shimada K., Sano T., Sakamoto Y., Kosuge T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer 2005, 104:1939-1947.
4. Poon R.T., Fan S.T., Ng I.O., Lo C.M., Liu C.L., Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89:500-507.
5. Kiyosawa K., Umemura T., Ichijo T., Matsumoto A., Yoshizawa K., Gad A., Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004, 127(5 Suppl. 1):S17-S26.
6. Jonas S., Bechstein W.O., Steinmüller T., Herrmann M., Radke C., Berg T., Settmacher U., Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33(5):1080-1086.
7. Sumie S., Kuromatsu R., Okuda K., Ando E., Takata A., Fukushima N., Watanabe Y., Kojiro M., Sata M. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann. Surg. Oncol. 2008, 15(5):1375-1382.
8. Liu Y.N., Lee W.W., Wang C.Y., Chao T.H., Chen Y., Chen J.H. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005, 24(56):8277-8290.
9. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17(5):548-558. (Review).
10. Tun H.W., Marlow L.A., von Roemeling C.A., Cooper S.J., Kreinest P., Wu K., Luxon B.A., Sinha M., Anastasiadis P.Z., Copland J.A. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 2010, 5(5):e10696.
11. Tomaskovic-Crook E., Thompson E.W., Thiery J.P. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009, 11(6):213. (Review).
12. Wong P.P., Pickard A., McCance D.J. P300 alters keratinocyte cell growth and differentiation through regulation of p21(Waf1/CIP1). PLoS One 2010, 5(1):e8369.
13. Vernon A.E., LaBonne C. Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr. Biol. 2004, 14(17):R719-R721. (Review).
14. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000, 14(13):1553-1577. (Review).
15. Spiegelman B.M., Heinrich R. Biological control through regulated transcriptional coactivators. Cell 2004, 119(2):157-167. (Review).
16. Vo N., Goodman R.H. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 2001, 276(17):13505-13508.
17. Ida K., Kitabayashi I., Taki T., Taniwaki M., Noro K., Yamamoto M., Ohki M., Hayashi Y. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 1997, 90(12):4699-4704.
18. Ionov Y., Matsui S., Cowell J.K. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc. Natl. Acad. Sci. USA 2004, 101(5):1273-1278.
19. Takahashi K., Kudo J., Ishibashi H., Hirata Y., Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. Hepatology 1993, 17(5):794-799.
20. Koshiishi N., Chong J.M., Fukasawa T., Ikeno R., Hayashi Y., Funata N., Nagai H., Miyaki M., Matsumoto Y., Fukayama S. P300 gene alterations in intestinal and diffuse types of gastric carcinoma. Gastric Cancer 2004, 7(2):85-90.
21. Zhang C., Li K., Wei L., Li Z., Yu P., Teng L., Wu K., Zhu J. P300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J. Clin. Pathol. 2007, 60(11):1249-1253.
22. Ishihama K., Yamakawa M., Semba S., Takeda H., Kawata S., Kimura S., Kimura W. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J. Clin. Pathol. 2007, 60(11):1205-1210.
23. Heemers H.V., Debes J.D., Tindall D.J. The role of the transcriptional coactivator p300 in prostate cancer progression. Adv. Exp. Med. Biol. 2008, 617:535-540.
24. Peña C., García J.M., García V., Silva J., Domínguez G., Rodríguez R., Maximiano C., García de Herreros A., Muñoz A., Bonilla F. The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int. J. Cancer 2006, 119(9):2098-2104.
25. Bedossa P., Peltier E., Terris B., Franco D., Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995, 21:760-766.
26. Tsai J.F., Chuang L.Y., Jeng J.E., Yang M.L., Chang W.Y., Hsieh M.Y., Lin Z.Y., Tsai J.H. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine (Baltimore) 1997, 76:213-226.
27. Fransvea E., Angelotti U., Antonaci S., Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008, 47(5):1557-1566.
28. Kung A.L., Wang S., Klco J.M., Kaelin W.G., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 2000, 6(12):1335-1340.
29. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70(5):1469-1480. (Review).
30. Xu K., Ding Q., Fang Z., Zheng J., Gao P., Lu Y., Zhang Y. Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. Cancer Gene Ther. 2010, 17(3):212-222.
31. Yang M.H., Wu M.Z., Chiou S.H., Chen P.M., Chang S.Y., Liu C.J., Teng S.C., Wu K.J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008, 10(3):295-305.
32. Umemura A., Itoh Y., Itoh K., Yamaguchi K., Nakajima T., Higashitsuji H., Onoue H., Fukumoto M., Okanoue T., Fujita J. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology 2008, 47(2):493-502.
33. Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C. P53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993, 14(5):987-992.
34. Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J., Ozturk M. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 1993, 7(14):1407-1413.
35. Iyer N.G., Ozdag H., Caldas C. P300/CBP and cancer. Oncogene 2004, 23(24):4225-4231.
36. Balsara B.R., Pei J., De Rienzo A., Simon D., Tosolini A., Lu Y.Y., Buetow K.H., London W.T., Testa J.R. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 2001, 30(3):245-253. (Review).
37. Li M., Luo R.Z., Chen J.W., Cao Y., Lu J.B., He J.H., Wu Q.L., Cai M.Y. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J. Transl. Med. 2011, 9:5.
38. Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T., Shioya H., Utsugisawa Y., Yokoyama K., Weichselbaum R., Shi Y., Kufe D. Role for p300 in stabilization of p53 in the response to DNA damage. J. Biol. Chem. 1999, 274(4):1883-1886.
39. Lim S.O., Kim H., Jung G. P53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS Lett. 2010, 584(11):2231-2236.
40. Blagosklonny M.V., An W.G., Romanova L.Y., Trepel J., Fojo T., Neckers L. P53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 1998, 273(20):11995-11998.
41. Vleugel M.M., Shvarts D., van der Wall E., van Diest P.J. P300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum. Pathol. 2006, 37(8):1085-1092.
42. Schmid T., Zhou J., Köhl R., Brüne B. P300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem. J. 2004, 380(Pt 1):289-295.
43. Brahimi-Horn C., Mazure N., Pouysségur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell. Signal. 2005, 17(1):1-9. (Review).